Drugs / Pseudoephedrine
Pseudoephedrine
also known as
Pseudoephedrine HCl · PSE · Pseudoephedrine Hydrochloride · Actifed · Acunaso · Afrinol · Contac · D-pseudoephedrine sulfate · +65 more
Small molecule targets SLC6A2
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Aerinaze | — | 2007-07-30 | europa.eu ↗ |
| Approved | US (FDA) | DISOPHROL | — | 1963-10-18 | fda.gov ↗ |
Trials 42
19621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02149901 | Oct 2014 → Dec 2020 | multiple system atrophy | Vanderbilt University | Terminated | No outcome recorded Stop: Business |
| Phase 110 trials | ||||||
| Phase 1 | NCT03644576 | Jul → Sep 2018 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03184766 | Aug 2016 → Jan 2017 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 1 | NCT03429738 | Apr → May 2014 | headache disorder | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01925729 | Oct 2013 → Mar 2019 | allergic rhinitis, otitis media | Cuneyt M. Alper | Completed | No outcome recorded |
| Phase 1 | NCT01577459 | Apr → Jun 2012 | — | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00932256 | Oct 2009 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00881127 | Jul 2005 | allergic disease | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00179023 | Apr 2003 → Jan 2017 | hypertensive disorder, obesity disorder, pure autonomic failure | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | Mixed |
| Phase 1 | NCT02182531 | Aug → Oct 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02082054 | Mar → May 2014 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00804687 | Nov 2008 → Feb 2009 | allergic rhinitis | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Missed primary |
| Phase 2 | NCT00240812 | ? → Nov 2002 | enuresis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 312 trials · 1 missed | ||||||
| Phase 3 | NCT05637710 | Mar 2026 → May 2027 | allergic rhinitis | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01744106 | Nov 2012 → Apr 2016 | common cold | Perrigo Company | Completed | No outcome recorded |
| Phase 3 | NCT01586962 | May 2012 | respiratory tract infectious disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01199497 | Aug 2011 → Aug 2012 | nasal cavity disorder | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01509209 | May 2011 → Apr 2013 | vasomotor rhinitis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT01293201 | Mar → Jun 2011 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01306721 | Feb → Apr 2011 | seasonal allergic rhinitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01055756 | Jan → Apr 2010 | allergic rhinitis | Azidus Brasil | Withdrawn | No outcome recorded |
| Phase 3 | NCT00963443 | Sep 2009 → Mar 2012 | common cold | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00276016 | Jan → Feb 2006 | seasonal allergic rhinitis | Organon and Co | Completed | Missed primary |
| Phase 3 | NCT02182518 | May 2000 → Jul 2001 | perennial allergic rhinitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01085721 | — | viral respiratory tract infection | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 49 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT05720455 | Jun → Dec 2025 | allergic rhinitis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04332211 | May 2021 → Jul 2023 | otorhinolaryngologic disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT03443843 | Feb → May 2018 | allergic rhinitis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT02246166 | Jan → Feb 2015 | common cold | GlaxoSmithKline | Completed | Missed primary |
| Phase 4 | NCT02175485 | Jun 2014 | allergic rhinitis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01202279 | Oct 2009 → Apr 2010 | respiratory tract infectious disorder | Reckitt Benckiser Inc. | Completed | Met primary |
| Phase 4 | NCT00441246 | Feb → May 2007 | bronchitis, respiratory tract infectious disorder, sinusitis | Adams Respiratory Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT00378144 | Jan 2007 → Mar 2008 | common cold, headache disorder, nasal cavity disorder | McNeil AB | Completed | No outcome recorded |
| Phase 4 | NCT00208065 | May 2004 → Nov 2005 | migraine disorder, sinusitis | Clinvest | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT05692869 | Jan → Apr 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT05697328 | Jan 2023 → Jul 2026 overdue | — | John Muir Health | Recruiting | No outcome recorded |
| — | NCT04682184 | Jan → Mar 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT00474890 | Jun → Dec 2007 | IgE responsiveness, atopic, rhinitis | Fraunhofer-Institute of Toxicology and Experimental Medicine | Completed | No outcome recorded |
| — | NCT00334698 | Jul → Sep 2006 | seasonal allergic rhinitis | Fraunhofer-Institute of Toxicology and Experimental Medicine | Completed | No outcome recorded |
| — | NCT00837915 | Jun → Aug 2002 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT00002149 | — | HIV infectious disease, sinusitis | Immune Enhancement Project | Completed | No outcome recorded |
| Comparator or background therapy15 trials | ||||||
| Phase 1 | NCT00881634 Comparator | Jun → Jul 2005 | allergic disease | Sandoz | Completed | No outcome recorded |
| Phase 1/2 | NCT03383887 Comparator | Dec 2017 → Jan 2020 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01033396 Comparator | Jan → May 2010 | allergic rhinitis | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00673062 Comparator | May → Jul 2008 | seasonal allergic rhinitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00000752 Background | ? → Feb 1993 | HIV infectious disease, sinusitis | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 3 | NCT01393548 Comparator | Aug 2014 → Nov 2016 | rhinitis | Ache Laboratorios Farmaceuticos S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01177852 Background | Oct 2011 → Apr 2012 | rhinitis | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01228630 Background | Aug 2011 → Apr 2012 | perennial allergic rhinitis | Azidus Brasil | Completed | No outcome recorded |
| Phase 3 | NCT00704496 Comparator | Jun 2007 → Sep 2009 | perennial allergic rhinitis | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01062360 Comparator | Dec 2005 → May 2007 | common cold, pharyngitis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT06907355 Background | May → Nov 2025 | respiratory tract infectious disorder | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT00648973 Comparator | Nov 2006 → May 2007 | nasal cavity disorder | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4 | NCT00377403 Background | Oct 2006 → May 2009 | respiratory tract infectious disorder, sinusitis | Washington University School of Medicine | Completed | Missed primary |
| — | NCT02065440 Comparator | Sep 2011 → Feb 2014 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT01028014 Comparator | Apr 2010 → Apr 2011 | urethral disorder | University of Alabama at Birmingham | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2015-03-23 | Acura Pharmaceuticals Inc. | Results Acura Pharmaceuticals Reports Successful Topline Results From Nexafed(R) Extended-Release Clinical Study acurapharm.com ↗
NEXAFED formulation B met FDA's standards for bioequivalence for maximum plasma concentration (Cmax) and extent of absorption (AUC). |
| 2013-09-03 | Acura Pharmaceuticals Inc. | Results Research Confirms New Nasal Decongestant Product Is Highly Meth-Resistant Yet Offers Same Effectiveness as Leading Pseudoephedrine Brand acurapharm.com ↗ |
| 2008-03-06 | Perrigo Company | Regulatory Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets perrigo.com ↗
has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for over-the-counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets, 5 mg/120 mg. |
| 2003-11-14 | Perrigo Company | Regulatory Perrigo Company Announces Approvals to Market Three New Products perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO) today announced that it will begin marketing three new products following U.S. Food and Drug Administration (FDA) approvals. |
| 2001-06-07 | Perrigo Company | Regulatory Perrigo Announces Approval to Market Ibuprofen and Pseudoephedrine Tablets perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO) today announced that it has received approval to market and distribute Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP, 200 mg and 30 mg respectively, through a development agreement with Ohm Laboratories, Inc., a subsidiary of Ranbaxy Pharmaceuticals Inc. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-03-23 | Acura Pharmaceuticals Inc. | Acura Pharmaceuticals Reports Successful Topline Results From Nexafed(R) Extended-Release Clinical Study acurapharm.com ↗ |
| 2013-09-03 | Acura Pharmaceuticals Inc. | Research Confirms New Nasal Decongestant Product Is Highly Meth-Resistant Yet Offers Same Effectiveness as Leading Pseudoephedrine Brand acurapharm.com ↗ |
| 2009-11-03 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Introduces Fexofenadine HCL and Pseudoephedrine HCL Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets tevapharm.com ↗ |
| 2008-03-06 | Perrigo Company | Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets perrigo.com ↗ |
| 2003-11-14 | Perrigo Company | Perrigo Company Announces Approvals to Market Three New Products perrigo.com ↗ |
| 2001-06-07 | Perrigo Company | Perrigo Announces Approval to Market Ibuprofen and Pseudoephedrine Tablets perrigo.com ↗ |
Evidence & citations 78 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pseudoephedrine | “The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine...” NCT01293201 ↗54“The investigational drug consists of a fixed-dose combination (FDC) that contains levocetirizine, a second-generation anti-H1 antihistamine agent, and pseudoephedrine, an oral...” NCT05637710 ↗ “Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief in Support of a Wait-and-See Approach for the Treatment of Acute Upper Respiratory Tract...” PMID 28761581 ↗ Apr 2017 “Evaluation of Efficacy of Dellegra® Combination Tablet (Fexofenadine Hydrochloride 30mg /Pseudoephedrine Hydrochloride 60mg) in Allergic Rhinitis After Japanese Cedar Antigen...” NCT02175485 ↗ “Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg,...” NCT02246166 ↗ “This is a randomized, double-blinded, placebo-controlled, crossover study to evaluate the pressor effects of pseudoephedrine when administered with TR-701 FA in healthy adult...” NCT01577459 ↗ “Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with "M27" on scored side and plain on the other side” NCT02082054 ↗ “Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.” NCT00932256 ↗ “Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.” NCT02065440 ↗ “one night of pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D) to placebo administered prior to sleep.” PMID 33491327 ↗ Jan 2021 “Codeine 10mg/5ml + Pseudoephedrine 7.5mg/5ml + Chlorphenamine 0.5mg/5ml: 10ml three times per day during 4 days” NCT06907355 ↗ |
| Known as | Actifed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Acunaso | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Afrinol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Contac | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | D-pseudoephedrine sulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Dimotane plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Dimotane plus l.a. | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Efidac 24 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Galpseud | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Galpseud plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Galsud | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Isoephedrine, d- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Neodurasina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Novafed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | NSC-106567 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | NSC-33634 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Otrinol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Otrivine mu-cron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | PSE | “The aims of this study were to characterize the multiple-dose pharmacokinetics (PK) of ozanimod's major active metabolites (CC112273 and CC1084037) and to evaluate the...” PMID 33025342 ↗ Oct 20202“a combination of cetirizine (CET) and pseudoephedrine (PSE), shows an equivalent treatment effect within and outside of the grass pollen season when tested in an ECC.” PMID 21457883 ↗ Feb 2011 “30 mg Pseudoephedrine (PSE), to be taken orally” NCT01062360 ↗ |
| Known as | Pseudo-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoefedrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine HCl | “Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)” NCT00441246 ↗4“Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)” NCT00881634 ↗ “Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets” NCT03429738 ↗ “Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)” NCT00881127 ↗ |
| Known as | Pseudoephedrine Hydrochloride | “Evaluation of Efficacy of Dellegra® Combination Tablet (Fexofenadine Hydrochloride 30mg /Pseudoephedrine Hydrochloride 60mg) in Allergic Rhinitis After Japanese Cedar Antigen...” NCT02175485 ↗2“A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride 200 mg/30 mg Tablets Under Fasting Conditions” NCT03429738 ↗ |
| Known as | Pseudoephedrine hydrochloride component of actahist | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of actifed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of advil allergy sinus | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of aleve-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of allegra-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of allerfed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of benylin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of bromanate dm | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of bromfed-dm | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of children's advil cold | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of children's motrin cold | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of codimal-l.a. 12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of corphed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of dimetane-dx | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of histafed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of hycofenix | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of isoclor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of mucinex d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of myfed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of rezira | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of semprex-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of sine-aid ib | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of triacin-c | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of trilitron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of triphed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of zutripro | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine hydrochloride component of zyrtec-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | PSEUDOEPHEDRINE POLISTIREX | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | PSEUDOEPHEDRINE SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of brompheril | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of clarinex-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of claritin-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of disobrom | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of disophrol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of drixoral | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of drixoral plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of resporal | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulfate component of trinalin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudoephedrine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudophed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Pseudophedrine HCl | “Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg” NCT02175485 ↗ |
| Known as | Rhinalair | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | SCH 4855 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Sinutab | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Sudafed | “pseudoephedrine ( Sudafed )” NCT00002149 ↗ |
| Known as | Sudafed 12 hour | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Sudafed 12 hr decongest | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Sudafed 24 hour | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Sudafed plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Known as | Sudafed-sa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1590 ↗ |
| Action | Activate | “effect of sympathetic stimulation with pseudoephedrine” NCT00179023 ↗ |
| Modality | Small molecule | — CHEMBL1590 ↗ |
| Route | Oral | “oral Deconsal II, a drug combining pseudoephedrine, a decongestant, and guaifenesin” NCT00000752 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter releasing agent” CHEMBL1590 ↗ |